Copenhagen, Denmark, 20 April 2023 – Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the appointment of Peter Adamson as Chief Scientific Officer (CSO) and Gabriela Burian as a new member of its Board
More
By Alexei Voloshin, Global Head of Bioprocess Science, 3M Biopharmaceutical Purification Article
By Alexei Voloshin, Global Head of Bioprocess Science, 3M Biopharmaceutical Purification Article Synopsis: Modern biotechnology has brought a revolution in
More
Copenhagen, Denmark, 20 April 2023 – Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases
More
